1.Small-cell carcinoma of the ovary, hypercalcemic type: A report of two cases and review of related literature
Almaira S. Pagayao ; Jericho Thaddeus P. Luna
Philippine Journal of Obstetrics and Gynecology 2024;48(3):190-196
Small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare and aggressive type of ovarian cancer. It generally presents in younger patients, is diagnosed at an advanced stage, and is associated with a dismal prognosis. Due to its rarity and morphologic similarity to more common ovarian tumors, diagnosis may be a challenge. A high index of suspicion followed by appropriate immunohistochemistry stains performed by an expert pathologist is essential to diagnosis. Two cases of SCCOHT are presented: 21 years old with rapidly progressive Stage IIIA1i disease who underwent surgery and succumbed to the illness after 3 months before adjuvant treatment could be given, and a 49 years old with Stage IIIB disease with tumor progression who is on adjuvant chemotherapy and apparently well, 21 months after her first symptoms appeared. Related literature is presented and compared to the features of the index cases. Diagnosis and treatment options are also discussed briefly.
ovarian cancer
;
ovarian neoplasms
2.Three ongoing intraperitoneal chemotherapy trials in ovarian cancer.
Journal of Gynecologic Oncology 2012;23(2):75-77
No abstract available.
Ovarian Neoplasms
3.Role and clinical application of next-generation sequencing (NGS) for ovarian cancer.
Myong Cheol LIM ; Leslie M RANDALL
Journal of Gynecologic Oncology 2017;28(4):e51-
No abstract available.
Ovarian Neoplasms*
4.Clinical significance of postoperative CA-125 level after primary cytoreductive surgery in ovarian cancer.
Journal of Gynecologic Oncology 2008;19(4):279-279
No abstract available.
Ovarian Neoplasms
5.Clinical significance of postoperative CA-125 level after primary cytoreductive surgery in ovarian cancer.
Journal of Gynecologic Oncology 2008;19(4):279-279
No abstract available.
Ovarian Neoplasms
6.Management of Advanced Epithelial Ovarian Cancer.
Korean Journal of Obstetrics and Gynecology 1999;42(8):1647-1654
No abstract available.
Ovarian Neoplasms*
7.A Short-Term In-Vitro Chemosensitivity Test for Ovarian Cancer: Nuclear Damage Assay.
Young Tak KIM ; Kwan Ja JI ; Yong Man KIM ; Joo Hyun NAM ; Jung Eun MOK
Korean Journal of Gynecologic Oncology and Colposcopy 1997;8(1):47-54
No abstract available.
Ovarian Neoplasms*
8.Do we need a better marker for successful ovarian cancer surgery?.
Journal of Gynecologic Oncology 2017;28(1):e21-
No abstract available.
Ovarian Neoplasms*
9.An immunohistochemical evaluation of c-erbB-2 expression in epithelial ovarian cancer.
Kyung Tai KIM ; Sam Hyun CHO ; Youn Yeoung HWANG ; Hyung MOON ; Jai Auk LEE ; Young Hye KO ; Jung Dal LEE
Korean Journal of Obstetrics and Gynecology 1993;36(8):3334-3342
No abstract available.
Ovarian Neoplasms*
10.Diagnostic accuracy performance of the International Ovarian Tumour Analysis (IOTA) simple rules and assessment of different neoplasias in the Adnexa (ADNEX) model for identifying benign or malignant Adnexal masses against histopathological diagnosis in patients seen and admitted at Dr. Jose Fabella Memorial Hospital
Geebee Mae M. Duran-Ranada ; Cynthia U. Anzures
Philippine Journal of Obstetrics and Gynecology 2019;43(3):9-21
Objective:
To know the diagnostic accuracy performance of the International Ovarian Tumour Analysis (IOTA) Simple Rules and Assessment of Different NEoplasias in the AdneXa (IOTA-ADNEX) Model for identifying benign or malignant adnexal masses against histopathological diagnosis.
Methods:
This was a prospective single-center, cross-sectional diagnostic accuracy study including 53 women with an adnexal mass between May 2017 and March 2018. Pelvic ultrasound examination was done and serum levels of tumor marker CA 125 were obtained in all subjects prior to surgery. Adnexal masses were categorized according to the IOTA Simple rules and IOTA ADNEX model. The gold standard was histopathological diagnosis. The sensitivity, specificity, positive and negative predictive values of each scoring system utilized was determined and compared with the histopathologic result.
Results:
Using the IOTA Simple rules, 35 adnexal masses classified as benign are 94.28 % truly benign by histopathologic diagnosis and 5.72% came out to be malignant; All 12 malignant tumors were truly malignant; there were 6 inconclusive tumors and came out to be malignant. In this study, IOTA Simple rules obtained a sensitivity of 90%, specificity of 100%, positive predictive value of 100%, Negative predictive value of 94% and Accuracy of 96%. Using the baseline risks assessment proposed by IOTA ADNEX Model, overall computation are as follows: (1) Sensitivity of 96.88 %, (2) Specificity of 90.48, (3) Positive Predictive Value of 93.94%, and a (4) Negative Predicitve Value of 95%
Conclusion
The majority of adnexal masses in our study were classified correctly using the IOTA Simple rules and IOTA ADNEX model. Due to high statistical significant values obtained by IOTA Simple rules, its use is validated and is encouraged to be the standard of use in scoring adnexal masses. In this study, we are able to prove that by subjective expert opinion from an expert sonographer in reclassifying those that are unclassified by IOTA simple rules approximates 100% accuracy.
Ovarian Neoplasms